title: Effects of cilostazol on thrombospondin-1 (TSP-1) expression changes in the myocardium of diabetic rats.
abstract: Myocardial protective effects of the phosphodiesterase 3 inhibitor, cilostazol, in streptozotocin-induced diabetic rats were investigated. Four weeks after induction of diabetes, we measured thrombospondin-1 (TSP-1) expression in the left ventricular myocardium. Microstructural and ultrastructural changes were also analysed. Four weeks after the induction of diabetes there were significant differences in body weight and blood glucose between the control, diabetic and cilostazol-treated diabetic animals. TSP-1 expression was significantly increased in the myocardium of diabetic rats compared with the control group. Although significantly higher than the control group, TSP-1 expression was significantly lower in the cilostazol group compared with the diabetes group. There were obvious ultrastructural changes in the myocardium of diabetic rats, which were rarely seen in cilostazol-treated diabetic rats. In conclusion, this study provides experimental evidence that cilostazol treatment of diabetic rats effectively prevents pathological myocardial alterations, possibly via the down-regulation of TSP-1 expression.
authors.affiliation: Department of Cardiovasology, The Second Affiliated Hospital School of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: J
authors.initials: J
authors.lastname: Ma
authors.forename: M
authors.initials: M
authors.lastname: Zheng
authors.forename: Y
authors.initials: Y
authors.lastname: Shen
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Zhu
authors.forename: X
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D002316:Cardiotonic Agents / Q000494:pharmacology; D000077407:Cilostazol; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D006321:Heart / Q000187:drug effects*; D006439:Hemodynamics; D008297:Male; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D013311:Streptozocin; D013777:Tetrazoles / Q000494:pharmacology*; D019700:Thrombospondin 1 / Q000235:genetics / Q000378:metabolism*
chemical_list: D001786:Blood Glucose; D002316:Cardiotonic Agents; D010726:Phosphodiesterase Inhibitors; D013777:Tetrazoles; D019700:Thrombospondin 1; D013311:Streptozocin; D000077407:Cilostazol